CLINICAL TRIALS PROFILE FOR METROGEL
✉ Email this page to a colleague
All Clinical Trials for metrogel
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00249782 ↗ | A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea. | Completed | Allergan | Phase 2 | 2005-11-01 | The purpose of this study is to evaluate the safety and effectiveness of ACZONE™ gel compared to placebo (inactive substance), MetroGel® and a combination of ACZONE™ gel and MetroGel® for the treatment of rosacea. ACZONE™ gel, 5% is a topical (applied to the skin) medication that is approved by the United States Food and Drug Administration (FDA) for the treatment of acne vulgaris in people 12 years and older. The use of ACZONE™ for the treatment of rosacea is investigational. An investigational use is one that is not approved by the FDA. Subjects will apply the study treatment for 12 weeks. Efficacy assessments will be performed at baseline and Weeks 2, 4, 8, and 12. Laboratory assessments will be conducted at baseline and Week, 2, 4 and 12. |
NCT00436527 ↗ | Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application | Completed | Galderma Laboratories, L.P. | Phase 4 | 2006-08-01 | This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application. |
NCT00635622 ↗ | Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis | Completed | University of California, San Francisco | Phase 2 | 2008-04-01 | This is a phase IIa clinical trial in women with bacterial vaginosis. This study will determine whether treatment with vaginal lactobacillus in combination with antibiotic therapy (metronidazole) is effective in colonizing the vagina with the lactobacillus bacteria found in normal vaginal flora. |
NCT00635622 ↗ | Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis | Completed | Osel, Inc. | Phase 2 | 2008-04-01 | This is a phase IIa clinical trial in women with bacterial vaginosis. This study will determine whether treatment with vaginal lactobacillus in combination with antibiotic therapy (metronidazole) is effective in colonizing the vagina with the lactobacillus bacteria found in normal vaginal flora. |
NCT00668655 ↗ | An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1% | Completed | Galderma Laboratories, L.P. | 2008-02-01 | The purpose of this study is to determine the cosmetic appearance of metronidazole gel (MetroGel®) 1% with commonly marketed facial foundations. | |
NCT01020396 ↗ | Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis | Completed | Teva Pharmaceuticals USA | Phase 1/Phase 2 | 2002-01-01 | The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M Pharmaceuticals' MetroGel-Vaginal® metronidazole vaginal gel, 0.75% to establish clinical equivalence in the treatment of bacterial vaginosis. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for metrogel
Condition Name
Clinical Trial Locations for metrogel
Trials by Country
Clinical Trial Progress for metrogel
Clinical Trial Phase
Clinical Trial Sponsors for metrogel
Sponsor Name